CAR-T cells, ADCs, and a new shot at lymphoma, the…

CAR-T cells, ADCs, and a new shot at lymphoma, the immunotherapy trifecta at ASCO 2026 Three immunotherapy strategies are being stress-tested this week in Chicago. For patients with relapsed blood cancers and solid tumors alike, the results could change what "second-line" even means. The era of one-size-fits-all chemotherapy is quietly ending. ASCO 2026 is showcasing the successor: precise, targeted immunotherapies tailored to the tumor's molecular identity. Cedars-Sinai's Lawrence Liu, MD, is presenting updated CAR